The Global Stimulant Boom Is Hitting a Treatment System Built for Opioids

Global cocaine production hit an all-time high in 2024: roughly 4,000 tonnes of pure product, a fourfold jump in a decade, according to the UN Office on Drugs and Crime’s World Drug Report 2026. Methamphetamine is scaling right alongside it — trafficking climbing an estimated 13 percent a year by seizure volume, per Al Jazeera’s reporting on the report, with production spreading into Africa, the Middle East, and Europe. There’s a specific accelerant, too: UNODC’s own research brief on Syria found that the collapse of the Captagon trade after Assad’s fall is pushing some users toward methamphetamine as the amphetamine-like pills get scarcer and pricier.

The US treatment system is not built for what’s coming, because it was built for a different drug.

Twenty years of opioid-focused federal money produced methadone clinics, buprenorphine prescribing pathways, and naloxone in every pharmacy and squad car. None of that treats stimulant use disorder. There is still no FDA-approved medication for cocaine or methamphetamine addiction — no methadone equivalent, no buprenorphine equivalent, nothing to hand a patient walking in with a stimulant problem while their treatment plan gets built around them.

The intervention with the strongest evidence base — contingency management, small cash or voucher rewards for verified negative drug tests — is both chronically underfunded and, more damning, legally hobbled. Providers serving Medicare and Medicaid patients have to navigate the federal Anti-Kickback Statute and the Beneficiary Inducements civil monetary penalty, which cap incentive payments at nominal amounts: CMS holds providers to roughly $75 a year, and some states set their own ceilings even lower. Health Affairs laid out the resulting bind plainly: the one treatment that reliably works for stimulant use disorder is treated by federal fraud regulators as a suspicious inducement rather than as medicine.

That’s the contradiction worth saying out loud. A system that will pay for lifelong opioid maintenance medication balks at paying someone $75 a year not to use meth, because the payment itself looks like the crime.

Stimulants don’t wait for policy to catch up. Production is scaling industrially, prices are falling, and purity is rising — the exact conditions that turned fentanyl into a mass-casualty event. A treatment system that only knows how to prescribe its way out of an epidemic is not equipped for the one arriving without a pill.